Overview

Phase I Study of TENPA in Advanced Solid Cancer

Status:
Terminated

Trial end date:
2019-07-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and to determine maximum tolerated dose and recommended phase 2 dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in patients with advanced solid tumor.

Phase:

Phase 1

Details

Lead Sponsor:

Yung-Jue Bang

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel